SMYD2 and breast cancer: Corresponding with elevated BCAR3 and SMYD2 levels, we detected a robust endogenous BCAR3 methylation signal using the specific BCAR3 K334me1 antibody in the metastatic breast cancer lines (Fig. 2e; Supplementary Fig. S2h, i).